^
    Apply
    P53MVA and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (NCT03113487)
    Phase 2
    City of Hope Medical Center
    Active, not recruiting
    Last update posted :
    02/19/2025
    Initiation :
    02/01/2018
    Primary completion :
    08/26/2022
    Completion :
    06/03/2025
    PD-L1 • TP53 • MUC16
    |
    TP53 mutation
    |
    Keytruda (pembrolizumab) • p53MVA
    CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma (NCT04870944)
    Phase 1/2
    Children's Oncology Group
    Recruiting
    Last update posted :
    02/13/2025
    Initiation :
    01/28/2022
    Primary completion :
    12/31/2026
    Completion :
    12/31/2026
    AFP
    |
    CBL137 IV
    Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy (NCT02432963)
    Phase 1
    City of Hope Medical Center
    Active, not recruiting
    Last update posted :
    03/19/2024
    Initiation :
    06/14/2016
    Primary completion :
    12/04/2017
    Completion :
    12/31/2024
    TP53 • MSI
    |
    TP53 mutation • TP53 expression • TP53 overexpression
    |
    Keytruda (pembrolizumab) • p53MVA
    Neoadjuvant/Adjuvant Chemotherapy, Vaccine & Adjuvant Radiation Therapy in p53-Overexpressing Stage III Breast Cancer (NCT00082641)
    Phase 1/2
    University of Nebraska
    Completed
    Last update posted :
    09/22/2023
    Initiation :
    01/01/2004
    Primary completion :
    05/01/2009
    Completion :
    01/01/2018
    TP53
    |
    TP53 overexpression
    |
    doxorubicin hydrochloride • cyclophosphamide • INGN 225
    SGT-53, Carboplatin, and Pembrolizumab for the Treatment of Metastatic Triple Negative Inflammatory Breast Cancer (NCT05093387)
    Phase 1
    Northwestern University
    Withdrawn
    Last update posted :
    11/15/2022
    Initiation :
    11/10/2022
    Primary completion :
    11/10/2022
    Completion :
    11/10/2022
    HER-2 • PD-L1
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • carboplatin • SGT-53
    SGT-53 in Children With Recurrent or Progressive CNS Malignancies (NCT03554707)
    Phase 1
    SynerGene Therapeutics, Inc.
    Not yet recruiting
    Last update posted :
    02/08/2022
    Initiation :
    06/01/2022
    Primary completion :
    12/01/2023
    Completion :
    12/01/2024
    MGMT • MDM2 • CDKN1A
    |
    ATRX mutation • MDM2 mutation
    |
    Avastin (bevacizumab) • temozolomide • irinotecan • Onivyde (nanoliposomal irinotecan) • SGT-53
    Effect and Safety of Recombinant Human Adenovirus Type 5 in Advanced HCC With Stable Disease After Sorafenib Treatment (NCT05113290)
    Phase 4
    First Affiliated Hospital Xi'an Jiaotong Univer...
    Active, not recruiting
    Last update posted :
    01/27/2022
    Initiation :
    12/28/2021
    Primary completion :
    12/01/2023
    Completion :
    12/01/2023
    AFP
    |
    sorafenib • Oncorine (recombinant human adenovirus type 5)
    Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors. (NCT03544723)
    Phase 2
    MultiVir, Inc.
    Recruiting
    Last update posted :
    06/09/2020
    Initiation :
    10/01/2018
    Primary completion :
    06/30/2022
    Completion :
    12/31/2022
    TP53
    |
    TP53 mutation • TP53 wild-type
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Tecentriq (atezolizumab) • Imfinzi (durvalumab) • Ad-p53 gene therapy
    Study of COTI-2 as Monotherapy or Combination Therapy for the Treatment of Malignancies (COTI2-101) (NCT02433626)
    Phase 1
    Critical Outcome Technologies Inc.
    Unknown status
    Last update posted :
    02/01/2019
    Initiation :
    12/01/2015
    Primary completion :
    12/01/2019
    Completion :
    06/01/2020
    TP53 • MUC16
    |
    TP53 mutation
    |
    cisplatin • COTI-2
    p53MVA Vaccine and Gemcitabine Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial Cancer (NCT02275039)
    Phase 1
    City of Hope Medical Center
    Completed
    Last update posted :
    04/30/2018
    Initiation :
    01/01/2015
    Primary completion :
    04/23/2018
    Completion :
    04/23/2018
    TP53 • MUC16
    |
    TP53 mutation • TP53 expression • TP53 overexpression
    |
    gemcitabine • p53MVA
    Vaccine Therapy in Treating Patients With Colorectal, Stomach, or Pancreatic Cancer (NCT01191684)
    Phase 1
    City of Hope Medical Center
    Completed
    Last update posted :
    08/01/2017
    Initiation :
    10/01/2011
    Primary completion :
    08/01/2013
    Completion :
    08/01/2013
    EGFR • TP53
    |
    TP53 expression • TP53 overexpression
    |
    p53MVA
    Systemic Chemotherapy Combined With Recombinant Human Adenovirus Type 5 and Endostatin Injections for Treatment Malignant Hydrothorax in NSCLC Patients (NCT02579564)
    Phase 3
    Xinqiao Hospital of Chongqing
    Unknown status
    Last update posted :
    10/21/2016
    Initiation :
    10/01/2016
    Primary completion :
    06/01/2018
    Completion :
    12/01/2018
    EGFR • MUC16
    |
    cisplatin • gemcitabine • paclitaxel • pemetrexed • vinorelbine tartrate • Endostar (recombinant human endostatin) • Oncorine (recombinant human adenovirus type 5)
    A Safety, Pharmacokinetic and Pharmacodynamic Study of Kevetrin in Patients With Advanced Solid Tumors (NCT01664000)
    Phase 1
    Cellceutix Corporation
    Completed
    Last update posted :
    02/24/2016
    Initiation :
    10/01/2012
    Primary completion :
    01/01/2016
    Completion :
    02/01/2016
    MUC16 • CDKN1A
    |
    Kevetrin (thioureidobutyronitrile)
    SCH-58500 in Treating Patients With Primary Ovarian, Fallopian Tube, or Peritoneal Cancer (C95084) (NCT00002960)
    Phase 1
    Merck Sharp & Dohme LLC
    Completed
    Last update posted :
    02/04/2016
    Initiation :
    06/01/1999
    Primary completion :
    07/01/2000
    Completion :
    07/01/2000
    TP53
    |
    TP53 mutation
    |
    Gendicine (rAd-p53 Gene Therapy)